X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AUROBINDO PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AUROBINDO PHARMA PANACEA BIOTECH/
AUROBINDO PHARMA
 
P/E (TTM) x 81.1 17.7 459.5% View Chart
P/BV x 1.8 5.7 31.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA
Mar-16
PANACEA BIOTECH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1491,541 9.7%   
Low Rs82582 14.1%   
Sales per share (Unadj.) Rs84.1237.5 35.4%  
Earnings per share (Unadj.) Rs-18.333.9 -54.0%  
Cash flow per share (Unadj.) Rs-6.740.6 -16.5%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7120.6 69.4%  
Shares outstanding (eoy) m61.25585.17 10.5%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x1.44.5 30.7%   
Avg P/E ratio x-6.331.3 -20.1%  
P/CF ratio (eoy) x-17.226.2 -65.9%  
Price / Book Value ratio x1.48.8 15.7%  
Dividend payout %07.4 0.0%   
Avg Mkt Cap Rs m7,074621,041 1.1%   
No. of employees `0002.813.3 20.7%   
Total wages/salary Rs m1,44915,508 9.3%   
Avg. sales/employee Rs Th1,874.110,457.6 17.9%   
Avg. wages/employee Rs Th527.01,167.1 45.2%   
Avg. net profit/employee Rs Th-407.71,491.6 -27.3%   
INCOME DATA
Net Sales Rs m5,154138,961 3.7%  
Other income Rs m1001,663 6.0%   
Total revenues Rs m5,254140,624 3.7%   
Gross profit Rs m-76632,056 -2.4%  
Depreciation Rs m7113,926 18.1%   
Interest Rs m1,5032,568 58.5%   
Profit before tax Rs m-2,88127,225 -10.6%   
Minority Interest Rs m1139 27.6%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m177,444 0.2%   
Profit after tax Rs m-1,12119,820 -5.7%  
Gross profit margin %-14.923.1 -64.5%  
Effective tax rate %-0.627.3 -2.1%   
Net profit margin %-21.814.3 -152.5%  
BALANCE SHEET DATA
Current assets Rs m3,810100,015 3.8%   
Current liabilities Rs m8,36574,759 11.2%   
Net working cap to sales %-88.418.2 -486.3%  
Current ratio x0.51.3 34.0%  
Inventory Days Days156107 145.0%  
Debtors Days Days67110 61.4%  
Net fixed assets Rs m14,48052,350 27.7%   
Share capital Rs m61585 10.5%   
"Free" reserves Rs m90367,707 1.3%   
Net worth Rs m5,12770,567 7.3%   
Long term debt Rs m5,8328,472 68.8%   
Total assets Rs m19,433156,994 12.4%  
Interest coverage x-0.911.6 -7.9%   
Debt to equity ratio x1.10.1 947.4%  
Sales to assets ratio x0.30.9 30.0%   
Return on assets %2.014.3 13.8%  
Return on equity %-21.928.1 -77.9%  
Return on capital %3.637.7 9.6%  
Exports to sales %24.551.0 48.0%   
Imports to sales %10.218.8 54.0%   
Exports (fob) Rs m1,26470,927 1.8%   
Imports (cif) Rs m52526,193 2.0%   
Fx inflow Rs m1,53971,015 2.2%   
Fx outflow Rs m94228,799 3.3%   
Net fx Rs m59742,216 1.4%   
CASH FLOW
From Operations Rs m59917,596 3.4%  
From Investments Rs m-438-13,801 3.2%  
From Financial Activity Rs m-303-198 152.6%  
Net Cashflow Rs m-1413,597 -3.9%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.0 7.5%  
FIIs % 1.3 27.7 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.2 231.4%  
Shareholders   10,259 69,601 14.7%  
Pledged promoter(s) holding % 35.1 8.6 409.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  MERCK LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plummets 390 Points; Infosys Continues to Fall(01:30 pm)

After opening the day on a negative note, the share markets in India continued to witness selling pressure as Infosys cracked after Vishal Sikka's resignation as MD & CEO.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 18, 2017 02:24 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS